Clinical Trial Update: UBT251 Injection Phase II Clinical Study (CKD) [Phase 2]

View source ↗

Summary

A Phase II clinical study of UBT251 for obesity and chronic kidney disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Obesity

Drugs mentioned

• UBT251

Snippet

Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. | Conditions: Obesity &Amp; Overweight, Chronic Kidney Disease | Phase 2 | Status: RECRUITING